Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference
Cidara Therapeutics (Nasdaq: CDTX) announced that CEO Jeffrey Stein and CFO James Levine will participate in investor meetings at the Raymond James Human Health Innovation Conference from June 21-23, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX) announced that CEO Jeffrey Stein and CFO James Levine will participate in investor meetings at the Raymond James Human Health Innovation Conference from June 21-23, 2021. The company focuses on developing long-acting therapeutics to address serious fungal and viral infections, with notable products including the antifungal candidate rezafungin and antiviral candidates from its Cloudbreak platform. Cidara is headquartered in San Diego, California.
Details
News Market Reaction – CDTX
The recorded move for CDTX in the trading session of this news was -2.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.